Devoted to the successful discovery, translation and development of therapeutics aimed at treating immune-mediated diseases, Beacon Immune Tolerance provides drug developers with a detailed view of the expanding immune tolerance drug development landscape.

The fight to improve outcomes for patients with immune mediated-diseases has taken a step forward following the publication of Beacon Intelligence’s Immune Tolerance Dataset. The dataset covers all pharmaceutical interventions used to treat autoimmune diseases, autoinflammatory diseases, alloimmune diseases and allergies.

Designed specifically to equip drug development scientists with crucial information to further their work, the Immune Tolerance Dataset provides unparalleled insights into the growing landscape of autoimmune therapies, helping researchers make faster and more informed decisions.

An Essential Resource for Drug Development Scientists

The Immune Tolerance Dataset is an essential resource that allows drug developers to track and analyze the latest advancements in therapies targeting immune-mediated diseases.

With more than 6,000 drugs (including over 2,400 clinically active and 1,400 that are in active pre-clinical development) and 12,000 clinical trials meticulously cataloged, Beacon’s dataset serves as the most comprehensive tool available to benchmark assets, analyze competitive landscapes, and stay up to date with the latest scientific breakthroughs.

Bella Glover, Immune Tolerance Research Analyst at Beacon comments: “We are committed to providing researchers with the most accurate and actionable data available so we can drive forward better outcomes for patients globally. With the launch of our Immune Tolerance Dataset, we are equipping drug development scientists with the resources they need to develop effective therapies efficiently, saving time and money.”

The Immune Tolerance Dataset

The dataset provides comprehensive coverage of all therapies treating autoimmune diseases, autoinflammatory diseases, alloimmune diseases and allergies including immunomodulators, immunostimulants, immunosuppressives and immune tolerance therapeutics.

Some of its key features include:

  • 6,000+ drugs, with 2,400+ in clinical development and 1,400+ in active preclinical development
  • 12,000+ trials, including 900+ active but not recruiting
  • 5,000+ developers engaged in immune-mediated disease research
  • In-depth categorization of drugs based on mechanism of action, autoantigen specificity, cell source, delivery system, and formulation
  • Rapid updates, ensuring the most current data is always available

Importantly, the dataset also includes a commercial intelligence and data expansion. This gives researchers unparalleled access to in-depth company profiles and the latest commercial deals, enabling them to monitor competitors and opportunities as well as evaluating potential partners.

How does the Immune Tolerance Dataset Work?

Beacon’s analytical tools, milestones filter and visualization technology make it easier than ever to navigate the complex immune tolerance research landscape. The platform provides detailed filters and data fields tailored to the needs of scientists, allowing them to:

  • Track new developments in autoimmune, autoinflammatory, alloimmune diseases, and allergies
  • Compare their pipeline assets against competitors in real time
  • Identify emerging trends in drug development and clinical trials
  • Make evidence-based strategic decisions with confidence

These data fields include:

  • Autoantigen Specificity
  • Mechanism of Action
  • Cell Source
  • Cell Type
  • Delivery System
  • Editing Technology
  • Target Organ/Cell
  • Formulation

Accelerating Immune Tolerance Development Programs

The Immune Tolerance dataset benefits Beacon’s clients by accelerating their immune tolerance development programmes. It enables scientists to:

  • Search therapeutics in the immune-disease space across all stages of development so you can accurately benchmark your strategies against all existing immune tolerance and immunomodulatory drugs, and investigate the novel technologies being used by competitors
  • Drastically reduce manual research time spent looking through publications and conference abstracts for preclinical and clinical trial results by relying on our comprehensive collection of data which can be searched by a variety of options including delivery system, cell type, disease indications and much more.
  • Stay on top of emerging trends and new players in the immune tolerance field with real-time updates and alerts, as well as in-depth monthly reports curated by our analyst team.

Bella Glover adds: “The immune tolerance landscape is evolving quickly, and it is therefore crucial for scientists to have access to accurate data. Generic databases often fail to provide the depth of insight needed for highly specialised fields such as immune tolerance research. Beacon’s Immune Tolerance Dataset fills this critical gap by offering a highly curated, niche focused solution designed to meet the needs of scientists working in this area.

Having access to detailed and up-to-date information can make the difference to a new therapy being developed successfully or not. This dataset not only enhances our clients’ ability to track and analyze immune tolerance therapies but also helps them accelerate drug development, optimize clinical strategies, and ultimately improve patient outcomes.”

For further details, please visit https://beacon-intelligence.com/solutions/immune-tolerance/